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The grey zone (GZ; 45–54 CGG repeats in the FMR1 gene) is considered
a normal allele; however, several studies have found a high frequency of
GZ in movement disordered populations. Here, we describe neurological
features of fragile X-associated tremor/ataxia syndrome (FXTAS) in two
carriers of GZ alleles, although FXTAS has been defined as occurring only
in premutation carriers (55–200 CGG repeats). Both patients had family
members who had premutation and were diagnosed with FXTAS. The
presence of relatively high GZ alleles with elevated fragile X mental
retardation 1 mRNA (FMR1 -mRNA) combined with a family history of
FXTAS that may represent a facilitating genetic background for FXTAS
are the factors that led to the presence of FXTAS in these individuals with
a GZ allele. Further research into clinical involvement of GZ alleles is
recommended and the definition of FXTAS may require revision.
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In 2001, the first five cases of the fragile X-associated
tremor ataxia syndrome (FXTAS) were described and
subsequent studies have validated the clinical features
of intention tremor, cerebellar ataxia, autonomic dys-
function, neuropathy, and cognitive decline (1, 2). The
cause of FXTAS is thought to be the elevated fragile
X mental retardation 1 mRNA (FMR1 -mRNA) lev-
els observed in all premutation carriers (55–200 CGG
repeats in the FMR1 gene) leading to RNA toxicity in
the neural cells (3).
The grey zone (GZ, 45–54 CGG repeats) allele is
considered normal. However, several researchers have
studied involvement in the GZ. Loesch et al. reported
more than twofold increased incidence of the GZ allele
in patients with Parkinsonism, one of the features in
FXTAS, and suggested a potential role for GZ in
neurodegeneration (4). A slightly elevated frequency
of GZ alleles was also found in male multiple system
atrophy (MSA) patients in European MSA populations
(5). Kenneson et al. found reduced fragile X mental
retardation protein levels in GZ alleles (6), whereas
Loesch et al. observed increased FMR1 -mRNA levels
for alleles as low as 39 CGG repeats in size (7). More
recently, Hall et al. reported three patients with FMR1
GZ alleles who met diagnostic criteria for FXTAS (8).
The consequence of these findings is the possibility
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of the development of FXTAS or related neurological
symptoms in some GZ carriers. The neurodegenerative
changes including FXTAS would likely be associated
with the toxic gain-of-function mechanism of raised
FMR1 -mRNA. Here, we report two carriers of GZ
alleles exhibiting FXTAS.
Clinical presentation of grey zone with FXTAS
Patient 1 is a 58-year-old male with a GZ of 52 CGG
repeats and his FMR1 -mRNA level is 1.83 ± 0.08-fold
above normal. He noticed tremor at age 55 when hold-
ing a coffee cup. At age 56, he noticed balance problems
and handwriting difficulties. He had numbness and tin-
gling in his feet. He has also had erectile dysfunction.
He has noticed some weakness in his hands including
a weak grip. His past medical history includes sleeping
problems, type II diabetes, hypertension, migraine
headaches, and eye surgery related to his diabetes.
Neurological examination
Finger to nose touching shows a bilateral intention
tremor with a significant terminal tremor. His motor
tone is increased on the left more than on the right.
He has great difficulty with tandem walking. Deep
tendon reflexes are 1+ in the upper extremities, 2+
at the knees, and absent at the ankles. Vibration sense
is decreased on the left side. He has a dyskinesia
with the right hand and a positive pull test. Brain
magnetic resonance imaging (MRI) demonstrated mild
brain atrophy and some scattered white matter disease
involving the pons but not the middle cerebellar
peduncles (MCPs) (Fig. 1).
Family history
His brother (II:3) has premutation and a GZ allele
(52,68 CGG repeats; mRNA 2.62 ± 0.34) and has been
diagnosed with FXTAS and previously been reported
(JDBP) (9). His brother has three daughters, one (III:2)
with GZ (56 repeats) and symptoms of anxiety and
two are premutation carriers [56 repeats (III:6) and 67
repeats (III:7), respectively]. The daughter with GZ has
two sons (IV:1 and IV:2) with premutation (61 and
69 CGG repeats) and autism. Another daughter (III:6)
has a daughter (IV:4) with premutation (69 repeats)
and symptoms of anxiety, attention deficit hyperactivity
disorder (ADHD) and shyness which are typically seen
in premutation carriers (Fig. 2).
Patient 2 is an 80-year-old female with a GZ of
53 CGG repeats and her FMR1 -mRNA level was
1.35 ± 0.07-fold above normal. Her neurological symp-
toms began at age 52 with an intermittent intention
tremor in her right hand. It began to involve her left
side within 2 years. At age 75, she developed balance
problems. At age 79, she began using a cane on
a regular basis. She had burning and numbness in
her lower legs. She has had autonomic dysfunction
including urinary frequency since age 55 and has also
been anorgasmic throughout her life. Other medical
problems include migraine headaches, osteoarthritis,
anxiety problems, and uterine and cervical cancer.
Her family history is significant in that her father
and uncle had FXTAS tremor and ataxia consistent
with FXTAS. Her uncle was seen before his death and
his neuropathology studies were documented with the
inclusions of FXTAS in both neurons and astrocytes
and his MRI had a MCP sign. Her uncle has three
daughters and all three have children diagnosed with
fragile X syndrome (Fig. 3).
Upon examination, a ‘no–no’ head tremor is per-
sistent throughout the exam. She has an intermittent
resting tremor in her hands and an intention tremor
bilaterally. She is ataxic, cannot tandem walk, and uses
a cane. Deep tendon reflexes are 1+ and symmetrical
in the upper extremities and her knees, absent at ankles.
Her vibration sense is decreased in both feet. Brain MRI
showed moderate to severe loss of the brain volume,
enlargement of the ventricles, and limited white mat-
ter disease (Fig. 1). Significant atrophy can also occur
in individuals who are 80 years old and it is likely
that a combination of atrophy from age and FXTAS are
present in this case, although her MRI demonstrates far
more atrophy than a control of her age (Fig. 1).
Discussion
FXTAS is defined as a premutation disorder (2, 10).
Patients 1 and 2 have most of the neurological features
of FXTAS but not a repeat number in the premutation
range as delineated by American College of Human
Genetics (ACHG) (11). The lower cut off for premuta-
tion at 55 repeats was set by ACHG related to a concern
for the risk of expansion to the full mutation in one
generation, but this delineation of CGG repeat number
does not take into account possible clinical involvement
of premutation or GZ carriers related to elevation of
FMR1 -mRNA. The cause of FXTAS is thought to be
the elevated FMR1 -mRNA, which is typically twofold
to eightfold in premutation carriers (12). However,
elevations in FMR1 -mRNA typically occur on a
continuum that starts in the GZ range (7). Loesch et al.
also observed a twofold increase of GZ alleles in males
with Parkinsonism. (4). More recently, increased levels
of the antisense FMR1 (ASFMR1 ) transcript were
described in a cohort of subjects with GZ and low pre-
mutation alleles and Parkinsonian phenotype suggesting
a potential cytotoxic effect of elevated levels of both the
FMR1 and ASFMR1 genes leading to mitochondrial
dysfunction and neurodegenerative disorders (13).
From the onset of the intention tremor, delay of
onset of ataxia was 1 year in patient 1 and, 23 years
in patient 2. A longitudinal study of FXTAS showed
that from the onset of intention tremor, median delay
of onset of ataxia was 2 years (14). When compared to
the progression in the above study, patient 2 had a much
slower progression, which is seen in many females with
FXTAS. The X-inactivation with a diluting effect of the
second normal X chromosome may have contributed to






Fig. 1. T1 and T2 weighted images of case 1, case 2 and normal control. (a) Showing mild atrophy of the cerebellum in case 1. (b) Showing
increased signal intensity in the left of the pons in case 1. (c) Showing atrophy of the temporal lobe in case 2. (d) Showing normal T2 weighted
images of normal control (female 83 years old). (e) Showing atrophy of the frontal lobe and enlargement of the ventricules in case 2. (f) Showing
normal T2 weighted images of normal control (female 83 years old).
when it occasionally occurs in GZ carriers, may
exhibit a slower deterioration in the GZ than in the
premutation.
Family members of both patients had premutation
and were earlier diagnosed with FXTAS; thus, it is
likely that these families have a facilitating genetic
background acting in concert with the premutation or
GZ to produce FXTAS. In both patients, the alleles
were in the upper GZ range with elevated FMR1 -
mRNA combined with a family background that could
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Fig. 2. Pedigree of the family of patient 1 (II:1, indicated with arrow).
His brother (II:3) has the premutation and GZ allele, and has been
diagnosed with FXTAS. His brother has three daughters, one with a GZ
(III:2) and two are premutation carriers (III:6 and III:7). The daughter
with the GZ has two sons with the premutation and autism (IV:1 and
IV:2) and III:6 has a daughter with the premutation allele (IV:4).
Fig. 3. Pedigree of the family of patient 2 (III:1, indicated with arrow).
Her father (II:1) and her uncle (II:3) are premutation carriers and both
have been diagnosed FXTAS. Her uncle (II:3) has three daughters
(III:3; III:5; and III:7) who have premutation alleles and all of them
have children who had been diagnosed with fragile X syndrome (IV:1;
IV:2; and IV:3).
lead to the observed symptoms of FXTAS. FXTAS
is the late outcome of an RNA-associated pathogenic
process that in mouse models actually begins early in
life, which may also be true in humans (15). However,
not all premutation carriers develop FXTAS so there
may be additional genetic or environmental factors
that facilitate the development of FXTAS. Here, we
propose that FXTAS may also be present in some GZ
carriers with the addition of facilitating genetic and
environmental factors.
Our report draws attention to the need for larger
studies in GZ carriers who may have a clinical picture
similar to FXTAS. Further neuropathological studies are
needed in GZ carriers, who succumb to neurological
problems, to clarify if indeed this is truly FXTAS with
the characteristic neuropathological features including
inclusions and spongiform changes in the white matter
(16). Although our patients did not have the classic
MCP sign seen in 60% of males and 13% of females
with FXTAS (17), their features are otherwise classic
for FXTAS and they meet criteria for probable FXTAS
(2). We therefore recommend that the definition of
FXTAS should not be limited to just the 55–200 repeat
range, but instead this definition should be broadened
to include the GZ, at least in the upper GZ allele CGG
repeat range and with facilitating genetic background.
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